Winners will be featured in the VETTY Awards booth inside the Expo Hall and receive an invitation ... Kit" by Boehringer ...

In a move described as a “more selective and paced approach” to drug development, Moderna outlined plans to reduce its annual R&D spending from the current $4.8 billion to between $3.6 billion and $3.

Vertilas GmbH invites you to join our team at Booth 4D021+4D022 during the China International Optoelectronic Exposition (CIOE) 2024 in Shenzhen on 11-13 September 2024. Vertilas will showcase its ...

Dehydration and diarrhea occur together as the body loses essential fluids. Learn why children and older adults are more ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Merck faces significant challenges, including increased competition and regulatory scrutiny for Keytruda. Keytruda is facing potential threats from competitors like Summit Therapeutics ...

Bongani Mthombeni has opened up about how the Matthew and Sonia Pule Booth 'cheesecake scandal' affected her for the first time since 2022. According to the businesswoman, living through the scandal ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...

Angela Rayner has been filmed raving in a DJ booth in Ibiza – after Sir Keir Starmer warned of “painful” times ahead for Britons. The Deputy Prime Minister was seen dancing at Hï Ibiza club ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

RAHWAY, N.J., August 29, 2024--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today provided updates on two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630.

In total, 169 patients participated in the survey; the majority of the patients stated their general health status as good (72.2%) and excellent (13.6%). Patients who rated their overall health status ...